Flagship Pioneering Inc. - Q4 2017 holdings

$394 Million is the total value of Flagship Pioneering Inc.'s 5 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 75.0% .

 Value Shares↓ Weighting
DNLI NewDENALI THERAPEUTICS INC$139,489,0008,918,749
+100.0%
35.37%
MCRB  SERES THERAPEUTICS INC$128,604,000
-36.8%
12,682,8760.0%32.61%
-52.1%
EDIT  EDITAS MEDICINE INC$51,455,000
+28.0%
1,674,4350.0%13.05%
-3.0%
QTRX NewQUANTERIX CORP$43,595,0002,030,495
+100.0%
11.06%
SYRS  SYROS PHARMACEUTICALS INC$31,179,000
-33.9%
3,204,4370.0%7.91%
-49.9%
TTOO ExitT2 BIOSYSTEMS INC$0-1,950,583
-100.0%
-2.74%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SERES THERAPEUTICS INC29Q3 202368.0%
DENALI THERAPEUTICS INC24Q3 202350.9%
SYROS PHARMACEUTICALS INC24Q2 202227.3%
MODERNA INC20Q3 202376.9%
EVELO BIOSCIENCES INC20Q1 202341.2%
RUBIUS THERAPEUTICS INC18Q4 202260.7%
Axcella Health Inc17Q2 20233.5%
KALEIDO BIOSCIENCES INC13Q1 20229.5%
Foghorn Therapeutics Inc12Q3 20236.5%
Sana Biotechnology Inc11Q3 202318.4%

View Flagship Pioneering Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
42024-02-14
13F-HR2023-11-14
42023-09-15
42023-08-15
13F-HR2023-08-14
42023-07-13
13F-HR2023-05-15
42023-02-27
13F-HR2023-02-14

View Flagship Pioneering Inc.'s complete filings history.

Compare quarters

Export Flagship Pioneering Inc.'s holdings